文献速递慢性肾脏病

基于适配体与基于抗体的检测方法在慢性肾脏病中蛋白质定量的比较

Comparison of Aptamer-Based and Antibody-Based Assays for Protein Quantification in Chronic Kidney Disease.
PubMed 文献 · Clin J Am Soc Nephrol · 2022-02-23

在498例AASK参与者中,以免疫测定为金标准,评估SOMAscan适配体技术对8种免疫激活生物标志物和胱抑素C的定量效果。发现IL-8、TNFRSF1B、胱抑素C、TNFRSF1A、IL-6和suPAR在两种方法间相关性不可忽略,而IL-10、IFN-γ和TNF-α不相关;免疫测定与不良结局的关联平均强于SOMAscan。

要点

  • SOMAscan与免疫测定在IL-8、TNFRSF1B、胱抑素C、TNFRSF1A、IL-6和suPAR间相关性不可忽略。
  • IL-10、IFN-γ和TNF-α在两种方法间不相关。
  • 免疫测定与不良结局的关联平均强于SOMAscan对应测定。

核心结论

  • SOMAscan是定量CKD中IL-8、TNFRSF1B、胱抑素C和TNFRSF1A的一种高效且相对可靠的技术,并能检测其与临床结局的潜在关联。

研究设计与样本

  • 在498例非洲裔美国人肾脏病与高血压研究(AASK)参与者中,以免疫测定为金标准,评估SOMAscan适配体技术对8种免疫激活生物标志物和胱抑素C的定量。

主要发现

  • SOMAscan与免疫测定间相关性不可忽略的生物标志物为IL-8(r=0.94)、TNFRSF1B(r=0.93)、胱抑素C(r=0.89)、TNFRSF1A(r=0.85)、IL-6(r=0.46)和suPAR(r=0.23)。
  • IL-10(r=0.08)、IFN-γ(r=0.07)和TNF-α(r=0.02)在SOMAscan与免疫测定间不相关。
  • 在相关性不可忽略的六种生物标志物中,TNFRSF1B、胱抑素C、TNFRSF1A和suPAR与测定的GFR负相关,并与更高的肾衰竭风险相关。
  • 通过两种方法,IL-8、TNFRSF1B、胱抑素C、TNFRSF1A和suPAR均与更高的死亡风险相关。
  • 平均而言,免疫测定与不良结局的关联强于SOMAscan对应测定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Novel aptamer-based technologies can identify >7000 analytes per sample, offering a high-throughput alternative to traditional immunoassays in biomarker discovery. However, the specificity for distinct proteins has not been thoroughly studied in the context of CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We assessed the use of SOMAscan, an aptamer-based technology, for the quantification of eight immune activation biomarkers and cystatin C among 498 African American Study of Kidney Disease and Hypertension (AASK) participants using immunoassays as the gold standard. We evaluated correlations of serum proteins as measured by SOMAscan versus immunoassays with each other and with iothalamate-measured GFR. We then compared associations between proteins measurement with risks of incident kidney failure and all-cause mortality. RESULTS: Six biomarkers (IL-8, soluble TNF receptor superfamily member 1B [TNFRSF1B], cystatin C, soluble TNF receptor superfamily member 1A [TNFRSF1A], IL-6, and soluble urokinase-type plasminogen activator receptor [suPAR]) had non-negligible correlations (r=0.94, 0.93, 0.89, 0.85, 0.46, and 0.23, respectively) between SOMAscan and immunoassay measurements, and three (IL-10, IFN-γ, and TNF-α) were uncorrelated (r=0.08, 0.07, and 0.02, respectively). Of the six biomarkers with non-negligible correlations, TNFRSF1B, cystatin C, TNFRSF1A, and suPAR were negatively correlated with measured GFR and associated with higher risk of kidney failure. IL-8, TNFRSF1B, cystatin C, TNFRSF1A, and suPAR were associated with a higher risk of mortality via both methods. On average, immunoassay measurements were more strongly associated with adverse outcomes than their SOMAscan counterparts. CONCLUSIONS: SOMAscan is an efficient and relatively reliable technique for quantifying IL-8, TNFRSF1B, cystatin C, and TNFRSF1A in CKD and detecting their potential associations with clinical outcomes. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2022_02_23_CJN11700921.mp3.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Lopez-Silva C, Surapaneni A, Coresh J, et al. Comparison of Aptamer-Based and Antibody-Based Assays for Protein Quantification in Chronic Kidney Disease. Clin J Am Soc Nephrol. 2022. PMID: 35197258. doi:10.2215/CJN.11700921

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。